Evidence map›Paper›PMID 34128759›Full record

SynthesisHuman vaccines & immunotherapeutics2022

Use of M-M-R II outside of the routinely recommended age range - a systematic literature review.

Manjiri Pawaskar, Elvira Schmidt, Gary S Marshall, Jaime Fergie, Elizabeth Richardson, Louise Parks Saldutti, Se Li, Monika Neumann, Linnea Koller, Barbara Kuter

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manjiri PawaskarMerck & Co., Inc., Kenilworth, NJ, USA.
Elvira SchmidtCertara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.ORCID 0000-0001-6159-4787
Gary S MarshallNorton Children's and University of Louisville School of Medicine, Louisville, KY, USA.ORCID 0000-0002-8731-6926
Jaime FergieTexas A&M University College of Medicine, Driscoll Children's Hospital, Corpus Christi, TX, USA.ORCID 0000-0002-1111-0892
Elizabeth RichardsonMerck & Co., Inc., Kenilworth, NJ, USA.
Louise Parks SalduttiMerck & Co., Inc., Kenilworth, NJ, USA.
Se LiFormer Employee of Merck & Co., Inc., Kenilworth, NJ, USA.
Monika NeumannCertara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.ORCID 0000-0001-8052-5429
Linnea KollerCertara Germany GmbH (Formerly Analytica Laser), Loerrach, Germany.ORCID 0000-0003-1674-4007
Barbara KuterFormer Employee of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

M-M-R®

Indexed as

MeaslesMumpsRubellaAged, 80 and overAntibodies, ViralAntigens, ViralHumansImmunization ScheduleInfantMeasles-Mumps-Rubella VaccineVaccines, CombinedAntibodies, ViralAntigens, ViralMeasles-Mumps-Rubella VaccineVaccines, CombinedageefficacyimmunogenicityinfantsmeaslesMMR vaccinemumpsrubellasafety

Identifiers

PMID34128759
PMCPMC8920138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.